Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06852222 |
Title | A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML) (cAMeLot-2) |
Acronym | cAMeLot-2 |
Recruitment | Not yet recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | Yes |
Sponsors | Janssen Research & Development, LLC |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | DNK |